SD (Sprague-Dawley) 랫드와 비글견을 이용한 신바로3 약침의 단회 근육투여 독성실험

이진호 ( Jin Ho Lee ),이인희 ( In Hee Lee ),이재웅 ( Jae Woong Lee ),김은지 ( Eun Jee Kim ),김민정 ( Min Jeong Kim ) 한방재활의학과학회 2015 한방재활의학과학회지 Vol.25 No.2

Objectives To assess the safety of Shinbaro3 Pharmacopuncture by analyzing the potential single-dose intramuscular toxicity of Shinbaro3 Pharmacopuncture at various dose levels in SD (Spraque-Dawley) rats and Beagle dogs. Methods For evaluation of single-dose intramuscular toxicity of Shinbaro3 Pharmacopuncture, 40 SD rats (20 male and 20 famale) and 4 Beagle dogs (2 male and 2 female) were used. The rats were divided in four groups of 10 each, and treated intramuscularly with Shinbaro3 Pharmacopuncture at doses of 0.3, 0.6 and 1.2 mg/kg in distilled water, and distilled water as a vehicle control group, respectively. The Beagle dogs were divided into two groups of 2 each, and treated intramuscularly with Shinbaro3 Pharmacopuncture at doses of 0.15, and 0.3 mg/kg in distilled water, respectively, and signs of toxicity were observed. After a wash-out period of 3 days, the procedure was repeated with Shinbaro3 Pharmacopuncture at doses of 0.6, and 1.2 mg/kg in distilled water, respectively. Mortality, body weight changes, and necropsy findings were examined during the study period. Results There were no mortalities in either the SD rats or Beagle dogs. There were also no significant differences in adverse effects, body weight, or necropsy findings between the Shinbaro3 Pharmacopuncture and control groups. Conclusions There results suggest that the lethal dose 50 (LD50) and approximate lethal dose (ALD) value of the test substance Shinbaro3 Pharmacopuncture are higher than 1.2mg/kg in SD rats and Beagle dogs. (J Korean Med Rehab 2015;25(2):73-80)

신바로3 약침시술을 병행한 한방치료로 호전된 극상근건염 및 삼각근하 점액낭염 환자 치험 1례

윤영웅 ( Yeong Ung Yun ),정재현 ( Jai Hyeon Chung ),정승현 ( Seong Hyun Cheong ),문병헌 ( Byung Heon Moon ),최영준 ( Young Jun Choi ),유수빈 ( Su Bin Yoo ),이정훈 ( Jung Hun Lee ),신동재 ( Dong Jae Shin ) 한방재활의학과학회 2015 한방재활의학과학회지 Vol.25 No.4

Objectives The objective of this study is to report the improved case of Korean medicine treatment with Shinbaro3 pharmacopuncture for supraspinatus tendinitis and subdeltoid bursitis. Methods We used Shinbaro3 pharmacopuncture with other Korean medicine treatment (acupuncture, herbal medicine, cupping and chuna) for this patient. This case is measured and assessed by Numerical Rating Scale (NRS), shoulder range of motion (ROM) and shoulder physical examination. Results The NRS decreased from 10 to 2 and the patient showed nearly full shoulder range of motion. Also physical examination of shoulder was improved. Conclusions Korean medicine treatment with Shinbaro3 pharmacopuncture is proved to be helpful to relieve pain and recover function on shoulder joint. (J Korean Med Rehab 2015;25(4):161-167)

극상근건염과 견봉하점액낭염 및 심각근하점액낭염으로 진단받은 견비통 환자를 대상으로 대용량 신바로 약침치료를 통한 통증경감과 가동범위 호전에 대한 증례보고

송광찬,서지연,송승배,조명의,최봉석,류원형,김두리,전용현 大田大學校 附屬 韓方病院 2017 惠和醫學 Vol.26 No.1

The purpose of this research is to show the effectiveness of the Korean medical treatment on patients diagnosed with supraspinatus tendinosis, subacromial bursitis and subdeltoid bursitis treated by Korean medical treatment Including megadose shinbaro pharmacopuncture. Methods : We used megadose shinbaro pharmacopuncture on patients who received treatment at Bucheon Jaseng Korean medicine hospital from December, 2016 to January, 2017. Also we checked NRS, SPADI, range of motion(ROM) and shoulder physical examination to follow the scale showing the improvement of the symptoms of the patients. Results : All 4 patientes showed the improvement of NRS, SPADI range of motion(ROM) and shoulder physical examination. Conclusion : This research showed that megadose shinbaro pharmacopuncture was effective on the treatment of shoulder pain patients diagnosed with supraspinatus tendinosis, subacromial bursitis and subdeltoid bursitis. 어깨 부위의 통증은 다양한 원인에 의해 발생되지만 대부분은 회전 근개 및 견봉하점액낭과 삼각근하점액낭의 염증에 의해서 발생된다1). 견관절 통증의 치료는 서양의학에서는 크게 보존적 치료와 수술적 치 료로 대별된다. 보존적 치료 방법으로는 휴식, 약물요법, 물리치료, 주 사요법 등이 있으며, 이러한 보존적 치료로도 증상 경감이 없을 경우 수술적 치료 방법을 고려할 수 있다2). 견관절 및 어깨 부위의 한의학적 치료는 침치료, 약침치료 및 한약치료를 같이 활용할 수 있다. 그 중에서도 약침치료는 효과적 인 치료법으로 많이 활용되고 있다3). 여러 가지 약침치료 방법 중에서 대용량 약침치료는 한의사가 변증결과를 바탕으로 여러 경혈 또는 유관 부위에 0.1∼수cc의 약침제제를 주입 하는 기존의 약침 치료형식과 다르게 MRI를 통한 해부학적 지식을 바탕으로 목표를 정하고 주입한다는 차별성이 있다. 용량은 요추 추간판탈 출증 환자에 대하여 4cc를 기준으로 사용한다4). 본 연구는 MRI상 극상근건염과 견봉하점액낭염 및 삼각근하 점액낭염으로 진단받은 환자를 대상으로 대용량 약침치료를 병 행한 한방치료를 시행한 결과 호전을 보인 사례가 있어 보고하 는 바이다.

교통사고 이후 MRI상 경추 추간판 탈출증 진단을 받은 환자에 대한 신바로약침과 봉약침의 치료효과 비교 연구: 후향적 환자군 관찰 연구

김기원,이민정,전재윤,임수진,이종환,김해솔,하인혁 대한침구의학회 2014 대한침구의학회지 Vol.31 No.1

Objectives : The purpose of this study is to compare the effect of Shinbaro pharmacopuncture treatment and bee venom pharmacopuncture treatment on cervical disc herniation and whiplash injury induced by traffic accident. Methods : This study was carried out on the 59 patients with whiplash injury by traffic accident and diagnosed as cervical disc herniation. The patients were divided into 2 groups ; Shinbaro pharmacopuncture group was treated with Shinbaro pharmacopuncture along with herbal medicine and general acupuncture. Bee venom pharmacopuncture group was treated with bee venom pharmacopuncture along with herbal medicine and general acupuncture. We measured verbal numerical rating scale(VNRS) and neck disability index(NDI) before the treatment and 1, 2, 3 weeks afterwards. Results : Shinbaro pharmacopuncture group and Bee venom pharmacopuncture both showed significant decrease in VNRS and NDI. Shinbaro pharmacopuncture group showed significant decrease over Bee venom pharmacopuncture group in VNRS decrement in the first week, while Bee venom pharmacopuncture group showed significant decrease over Shinbaro pharmacopuncture group in the secone week of treatment. Conclusion : According to the result of this study, it is suggested that Shinbaro pharmacopuncture group is more effective in reducing pain in the earlier period of treatment. Also suggests that further study on the effect of Shinbaro pharmacopuncture on patients diagnosed as cervical disc herniation after traffic accident for longer period of treatment.

신바로 약침의 국내 임상 연구 동향: 스코핑 리뷰

김영민,한윤희,최승관,조정호,전병현,우현준,하원배,이정한 한방재활의학과학회 2023 한방재활의학과학회지 Vol.33 No.4

Objectives This study aimed to investigate domestic clinical research trends in Shinbaro pharmacopuncture, identify diseases managed using Shinbaro pharmacopuncture, and suggest the direction for future studies to increase its clinical utilization. Methods This study used five steps proposed by Arksey and O'Malley and the PRISMA-extension for scoping reviews checklist. We examined published literature on Shinbaro pharmacopuncture studies reported until June 5, 2023, in the following eight databases (Research Information Sharing Service, Science ON, Oriental Medicine Advanced Searching Integrated System, KMBASE, The Society of Internal Korean Medicine, PubMed, EMBASE, and the Cochrane Library). The search terms used were ‘Shinbaro’ or ‘Sinbaro’. Results A total of 47 studies were included in our analysis. Of these, 37 (78.7%) were interference time series studies. Shinbaro pharmacopuncture was the most frequently used treatment for lumbosacral disease (n=15). In the facial area, ST4 and ST6 were used in five out of six studies, and in the shoulder area, TE14 and LI15 were used in all studies. Nine of the 15 studies in the lumbosacral area used the EX-B2. The other parts mostly used the pressure points. Compared to other pharmacopuncture methods, the treatment effect was similar to that of bee venom, and faster than that of jungsongouhyul. Conclusions This is the first scoping review of Shinbaro pharmacopuncture therapy in South Korea. Studies with a high level of evidence based on sole treatment, large capacities, and standardization of Shinbaro pharmacopuncture need to be conducted to increase its clinical utilization. (J Korean Med Rehabil 2023;33(4):125-144)

척추전방전위증 환자에 대한 신바로약침과 봉약침의 치료효과 비교 연구

노해린,박소현,이재영,추원정,한상욱,김신웅,손슬기,엄태웅,Ro, Hae-Rin,Park, So-Hyun,Lee, Jae-Young,Choo, Won-Jung,Han, Sang-Wook,Kim, Shin-Woong,Son, Seol-Ki,Eom, Tae-Woong 척추신경추나의학회 2012 척추신경추나의학회지 Vol.7 No.2

Objectives : The Purpose of this study is to compare the effect of ShinBaro Pharmacopuncture Treatment and Bee Venom Pharmacopuncture Treatment of low back pain and radicular pain caused by spondylolisthesis. Methods : From January 1st,2012 to September 30th, 2012, 30 Low back pain and radicular pain patients with spondylolisthesis who were admitted to Bu-Cheon Jaseng Hospital of Oriental Medicine were divided into two groups. ShinBaro group was treated by ShinBaro Pharmacopuncture Treatment and Bee Venom group was treated by Bee Venom Pharmacopuncture Treatment. We evaluated the treatment effect of each group with numerical rating scale(NRS) and Oswestry disability index(ODI). The evaluations performed at admission day and 14th day after admission. Results : In both ShinBaro group and Bee Venom group, NRS and ODI decreased significantly in ststistics as treatment was perfomed. Though ShinBaro group showed a decreasing ODI score compared to BV group and BV group showed a decreasing NRS score compared to Shinbaro group, There is no statistical significance on NRS and ODI score after the treatment in both groups. Conclusions : The result sugguest that both ShinBaro pharmacopuncture treatment and Bee Venom pharmacopuncture treatment is considered to be effective and useful on low back pain and radicular pain caused by spondylolisthesis, although further study is needed.

교통사고 후 발생한 편타 손상 환자에 대한 신바로약침과 중성어혈약침의 치료효과 비교연구

김태헌 ( Tae Hun Kim ),박원형 ( Won Hyung Park ),차윤엽 ( Yun Yeop Cha ) 한방재활의학과학회 2013 한방재활의학과학회지 Vol.23 No.4

ObjectivesThe purpose of this study is to compare the effects of ShinBaro pharmaco-puncture and Jungsongouhyul pharmacopuncture on whiplash injury by traffic accident.MethodsThis study was carried out on 30 patients who received treatment in Jaseng Hospital of Korean Medicine. 30 patients were divided ShinBaro pharmacopuncture group and Jungsongouhyul pharmacopuncture group. Visual analog scale (VAS) and neck dis-ability index (NDI) were compared after treatment.Results1) Both the ShinBaro group and Jungsongouhyul group showed significant im-provement in the visual analog scale (VAS) and neck disability index (NDI) after 3 weeks of treatment. 2) The VAS and NDI of the ShinBaro group decreased gradually with treatment. The VAS scores showed significant improvement up to week 2, but although week 3 showed further improvement compared to week 2, the difference did not reach statistical significance. The NDI scores showed significant improvement consistantly throughout the treatment period. 3) The VAS and NDI of the Jungsongouhyul group decreased with treat-ment also. The VAS scores significantly improved up to week 2, but though week 3 showed further improvement in comparison to week 2, the difference did not reach stat-istical significance. The NDI scores showed significant improvement consistantly through-out the treatment period. 4) Although the ShinBaro group showed a swifter decline than the Jungsongouhyul group in both VAS and NDI scores, the difference was not statistically significant.ConclusionsWe found out that ShinBaro pharmacopuncture group and Jungsongou-hyul pharmacopuncture group is effective and useful in whiplash injury by traffic accident. And, further studies will be needed. (J Korean Med Rehab 2013;23(4):1-7)

SD(Sprague-Dawley) 랫드를 이용한 신바로 약침의 4주 반복 근육투여 독성시험

이진호,하인혁,김미령,김민정,이재웅,이인희,정화진,김은지 대한침구의학회 2015 대한침구의학회지 Vol.32 No.4

Objectives: To evaluate the safety of multiple-dose intramuscular Shinbaro Pharmacopuncture in male and female Sprague-Dawley(SD) rats over a period of 4 weeks(12 sessions). Methods: In order to test the safety of multiple-dose intramuscular Shinbaro Pharmacopuncture we used 40 healthy male and female 6-week old SD rats(male weight 171.79~196.37 g, female weight 127.93~146.43 g). Shinbaro Pharmacopuncture was administered intramuscularly to male and female SD rats at doses of 4.6 (low dose group, n=10), 9.2 (moderate dose group, n=10), and 18.5 mg/kg(high dose group, n=10), respectively. General symptoms, body weight changes, blood tests, biochemical testing, necropsy, organ weight and histopathogical findings were examined over a 4-week period. Results: 1. No mortalities or adverse effects were caused by the investigational substance were ob- served during the study period. 2. There was no significant difference in body weight caused by the the investigational sub- stance across all groups. 3. No significant between-group difference was found to be caused by the investigational substance in blood tests and biochemical testing. 4. No abnormalities were detected by a necropsy examination with the unaided eye at the macro level after treatment with the investigational substance. 5. Difference in organ weight between groups caused by the investigational substance was not found. 6. All groups did not exhibit pathological findings caused by the investigational substance in histopathogical examination. Conclusions: According to these results, Shinbaro Pharmacopuncture has no systemic or organ toxicity with multiple-dose intramuscular administrations in male and female SD rats over a 4- week period (12 sessions). These results imply that no adverse effects are observed at a level (NOAEL) of Shinbaro Pharmacopuncture of 18.5 mg/kg.

방아쇠 수지 환자의 신바로 약침 치험례

이민수,강경래,최아련,정유진,강아현,한동근,송우섭,이형철,Lee, Min-su,Kang, Kyung-rae,Choi, A-ryun,Jung, You-jin,Kang, Ah-hyun,Han, Dong-geun,Song, Woo-sub,Lee, Hyung-chul 대한한방내과학회 2016 大韓韓方內科學會誌 Vol.37 No.2

Objective: This study investigates the clinical application of Shinbaro pharmacopuncture for trigger finger.Method: Because the effect of Shinbaro pharmacopuncture has been proven in various musculoskeletal cases, we treated a patient diagnosed with trigger finger using Shinbaro pharmacopunture. A 0-10 numerical rating scale (NRS) for pain and Quinnell’s classification for trigger finger were assessed before and after three Shinbaro pharmacopuncture treatments.Results: After treatments, the patient’s pain was controlled (without any side effects), and the NRS score decreased from 8 to 1. The Quinnell’s classification of trigger finger score also improved (from 3 to 1).Conclusion: This case has shown that Shinbaro pharmacopuncture treatment could be effective for treating the clinical symptoms of trigger finger.

신바로 약침의 SD 랫드와 비글견에 대한 단회 근육투여 독성시험

이진호 ( Jin Ho Lee ),정화진 ( Hwa Jin Chung ),이인희 ( In Hee Lee ),이재웅 ( Jae Woong Lee ),김은지 ( Eun Jee Kim ),김민정 ( Min Jeong Kim ) 한방재활의학과학회 2015 한방재활의학과학회지 Vol.25 No.3

Objectives To evaluate Shinbaro Pharmacopuncture safety through analysis of potential single-dose intramuscular toxicity of Sinbaro Pharmacopucture in SD rats and Beagle dogs. Methods Single-dose intramuscular toxicity of Shinbaro Pharmacopuncture was assessed in accordance with Korea Food and Drug Administration Guidelines for toxicity testing of Medicinal Products. The SD rats were treated intramuscularly with Shinbaro Pharmacopuncture at doses of 0, 4.6, 9.2, and 18.5 mg/kg, respectively. The Beagle dogs were treated intramuscularly with Shinbaro Pharmacopuncture at doses of 2.3, and 4.6 mg/kg, respectively, and after 3 days, the procedure was repeated a second time at doses of 0.6, and 1.2 mg/kg, respectively, for toxicity testing. Mortality, change in body weight, and necropsy findings were examined for the study period. Results There were no mortalities, general symptoms, or body weight changes in the SD rats. While pyelectasis of the left kidney was observed in a male rat in the 4.6 mg/kg administration group, natural occurrence is common, and does not appear to be related with the test substance. No mortalities were observed in the Beagle dogs. In assessment of general symptoms, a female dog in the 9.2 mg/kg group displayed body weight decrease due to leftover food, but the change in body weight was within the normal range seen at 6~7 months, and the necropsy findings were not significant. The toxicity of the test substance appears to be minimal. Conclusions The results suggest that the lethal dose 50 (LD50) and approximate lethaldose (ALD) value in single intramuscular administration of Shinbaro Pharmacopuncture in SD rats and Beagle dogs are higher than 18.5 mg/kg. (J Korean Med Rehab 2015;25(3):1-9)